No Data
No Data
China Accepts Shanghai Junshi Biosciences' Supplemental Application for Melanoma Treatment
Express News | Junshi Biosciences Announces Acceptance of Supplemental New Drug Application for Toripalimab as First-Line Treatment of Unresectable/Metastatic Melanoma
Express News | Shanghai Junshi Biosciences - Received Acceptance Notice Issued by Nmpa for New Drug Application for Toripalimab
Junshi Bio (688180.SH): application for market approval of Toripalimab monoclonal antibody as first-line treatment for melanoma received acceptance.
On August 12th, Gelunhui reported that Junshi Biosciences (688180.SH) received the "Acceptance Letter" issued by the National Medical Products Administration for the new indication application for Teriprizumab (trade name: Tuoyi, product code: JS001) for first-line treatment of unresectable or metastatic melanoma. The application for this new indication is primarily based on the MELATORCH study (NCT03430297). The MELATORCH study is a multi-center, randomized, open-label, positive drug-controlled phase III clinical trial and the first and only one in China at present.
Chinese scientists uncover the evolution direction of the novel coronavirus, drawing attention to the treatment drug industry chain.
Research results show that the new coronavirus will become a more adaptive circulating strain. In news, the World Health Organization warned at a press conference in Geneva that data from more than 80 countries showed a continuous increase in the number of people infected with the main pathogen of COVID-19, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The summary of the legal infectious disease situation in Guangdong Province in June and July 2024 published by the Guangdong Provincial Center for Disease Control and Prevention shows that the number of COVID-19 cases increased from 8246 in June to 18384 in July, an increase of more than 0.01 million.
Tracking of Hong Kong stock concepts | The Medical Insurance Bureau has announced the new medical insurance catalog. Institutions believe that the golden opportunity to increase the allocation of the pharmaceutical sector has already opened (including con
The National Medical Insurance Bureau has conducted preliminary reviews on 440 pharmaceuticals for this year's medical insurance catalog, which is an increase from last year.
No Data